Next Investors logo grey

MyFiziq teams up with Biomorphik to develop on-demand product


Published 17-SEP-2020 10:26 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

MyFiziq Limited (ASX: MYQ) has executed definitive agreements with Biomorphik Pty Ltd (Biomorphik), an Australian-based behavioural change and technology company.

Biomorphik has developed a medical health and wellness platform that is the bridge between medical and health/wellness with the aim of reducing health costs at all levels of society from the individual, to healthcare and insurance systems and governments.

The company has had a surge of interest in its product offering from governments and large corporations across Asia as a result of the current pandemic.

As a consequence of developments relating to the pandemic, Biomorphik has found that consumers, corporations and governments have developed a better understanding of the value of a healthy lifestyle and its impacts on individuals, families, business and economies.

This is an excellent fit with MyFiziq’s body scan technologies that have also come to market at a critical time as the demand for its products are accelerating.

New product to be launched in November

Under the commercial terms of the definitive agreements, Biomorphik and MyFiziq have commenced working together to build and release an initial product by 10 November, 2020.

This will use MyFiziq’s new Body Scan OnDemand product which comprises a set of standalone iOS and Android applications, branded in Biomorphik colours, linked to Biomorphik’s iOS and Android applications via cross-app deep linking.

In parallel with the accelerated time to market integration, the parties are also working on a full integration of the MyFiziq SDKs (Software Development Kit) into the new platform that Biomorphik is developing.

With a target release date of March quarter 2021, the new MyFiziq integrated Biomorphik platform will also include multi-language versions to target specific countries in Asia.

All aspects of new product to be customisable

All of MyFiziq's standard SDKs are included in the OnDemand version meaning that users have access to all the latest functionality offered by MyFiziq.

Meanwhile, authentication and payment options remain on the partner application.

This ensures that the OnDemand application can only be accessed via a partner application.

The OnDemand application has also been developed to be fully configurable by partners.

This means that branding, fonts and imagery as indicated below are fully customisable ensuring that user experience remains consistent between apps.

body scan

Targeting 100,000 active users in first 12 months

Commenting on this development, MyFiziq chief executive Vlado Bosanac said, “Biomorphik is our first partner to take advantage of our newly developed Body Scan OnDemand cross-linked iOS and Android applications, which we have built to get integrated products to market quicker, in turn enabling swifter user revenue generation for MyFiziq and our partners.

‘’As announced in August, Biomorphik originally confirmed a January 2021 MyFiziq integrated release.

‘’However, since then, Biomorphik has experienced a surge of new business interest in Asia due to the COVID-19 pandemic.

‘’In response to the surge in demand, we are now working with Nathaniel and his team to release the initial product to market by November 10, 2020, 3 months earlier than originally advised.’’

In conjunction with the express to market product, MyFiziq’s marketing team is assisting with a campaign to drive users throughout Asia to the Biomorphik platform.

The joint marketing campaign will focus on both user acquisition as user engagement and is targeted to commence in-line with the November 2020 release.

Biomorphik has undertaken a user target of 100,000 active users in the first 12 months and MyFiziq will play a role in achieving this target with a joint marketing campaign.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.